Updated:
Novalis LifeSciences
Novalis LifeSciences is an SEC-registered investment adviser with its headquarters in Hampton, NH. It provides investment advice to clients. The firm focuses...
Novalis LifeSciences
Novalis LifeSciences is an SEC-registered investment adviser with its headquarters in Hampton, NH. It provides investment advice to clients. The firm focuses on healthcare and life sciences investments.
General information
Firm type
Private Equity
Year founded
2017
AUM
$500M (per the firm)
Location
Region
North America
Country
United States
City
Hampton
Corporate office
170 Commerce Way, Suite 200, Portsmouth, NH 03801, USA
Additional offices
Boston, MA, USA
Principals
Marijn Dekkers
Chairman
Paul Meister
Partner
Dino Pantelis
COO
Devin Leake
Managing Director
Michael Alter
Managing Director
Greg Herrema
Senior Advisor
Sector focus
Frequently asked questions
Who runs investment decisions at Novalis LifeSciences?
Marijn Dekkers, the firm's Chairman and founder, leads investment decisions with Partner Paul Meister. Dekkers was previously CEO of Bayer and Thermo Fisher Scientific; Meister was Chairman of Thermo Fisher and co-founder of Liberty Lane Partners. The two draw on decades of operating experience running global life science companies.
How does Novalis LifeSciences source its deals?
Novalis sources deals partly through its dual structure: the Novalis Advisory unit provides strategic and investment banking services to life science companies, creating a pipeline of firms the partners already know operationally. The firm's senior team, including former Thermo Fisher executives, also leverages a deep network across the diagnostics, tools, and biopharma sectors.
What is the relationship between Novalis LifeSciences and Novalis Advisory?
Novalis LifeSciences is the direct investment vehicle that manages venture capital and private equity funds. Novalis Advisory is a separate unit under the same parent, Novalis Capital Partners, offering strategic advisory, investment banking, and leadership coaching to life science companies. The two entities share leadership and often interact with the same companies in different capacities.
Does Novalis LifeSciences invest at a specific stage?
The firm invests from early-stage venture rounds through growth and late-stage expansion, across life science tools, diagnostics, and biopharma. Portfolio companies span pre-revenue platform developers like Helaxy and commercial-stage public companies such as Cerevel Therapeutics before its acquisition.
Where does Novalis LifeSciences typically invest geographically?
Novalis invests globally, with current and exited portfolio companies headquartered in the United States, Germany, the United Kingdom, Belgium, the Netherlands, and Singapore. Its own offices are in Portsmouth, New Hampshire, and Boston, Massachusetts.
Has Novalis LifeSciences had notable exits?
Yes. Confirmed exits include Cerevel Therapeutics (acquired by AbbVie in August 2024), Decipher Biosciences (acquired by Veracyte in March 2021), Celsee (acquired by Bio-Rad in April 2020), and the public listings of Quanterix and Ginkgo Bioworks.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: